All In Biotech

Drug Trial Radar · NCT06311721

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

315

Actual

Start

Sep 9, 2024

Primary completion

Jan 10, 2028

Study completion Apr 24, 2028

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).

Conditions

  • Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Interventions

  • ABP 234Drug

    Intravenous administration

  • Pembrolizumab (US)Drug

    Intravenous administration

  • Pembrolizumab (EU)Drug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234Time frame: 21 days
  2. AUC21d of pembrolizumab (US)Time frame: 21 days
  3. AUC21d of pembrolizumab (EU)Time frame: 21 days
  4. AUC at steady state between Week 16 and Week 19 (AUCtau_ss) of ABP 234Time frame: Week 16 through Week 19
  5. AUCtau_ss of pembrolizumab (US)Time frame: Week 16 through Week 19
  6. AUCtau_ss of pembrolizumab (EU)Time frame: Week 16 through Week 19

Locations

218 sites in 23 countries. Site status is shown where the registry gives one.

  • Precision NextGen Oncology and Research Center

    Beverly Hills, California

  • TOI Clinical Research

    Cerritos, California

  • Cancer and Blood Specialty Clinic (CBSC)

    Los Alamitos, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • PIH Health Hospital

    Whittier, California

  • Millennium Oncology - Hollywood

    Hollywood, Florida

  • BRCR Medical Center Inc.

    Tamarac, Florida

  • Accellacare Duly

    Plainfield, Illinois

  • Accellacare of McFarland

    Ames, Iowa

  • Detroit Clinical Research Center, PC

    Farmington Hills, Michigan

  • North Shore Hematology-Oncology Associates P.C. d/b/a New York Cancer & Blood Specialists

    Shirley, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Millennium Research and Clinical Development, LLC

    Houston, Texas

  • Texas Oncology, P.A

    San Antonio, Texas

  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Wytheville, Virginia

  • IONC - Instituto Oncologico de Cordoba

    Córdoba, Argentina

  • Instituto de Investigaciones Clinicas Mar del Plata

    Mar del Plata, Buenos Aires, Argentina

  • Centro de Investigacion Pergamino SA

    Pergamino, Buenos Aires, Argentina

  • Fundacion ARS Medica

    San Salvador de Jujuy, Jujuy Province, Argentina

  • Sanatorio Britanico De Rosario

    Rosario, Santa Fe Province, Argentina

  • Hospital Provincial del Centenario

    Rosario, Santa Fe Province, Argentina

  • Klinikum Klagenfurt am Woerthersee

    Klagenfurt, Austria

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria

  • Hospital Nossa Senhora das Gracas

    Canoas, Brazil

  • CIONC - Centro Integrado de Oncologia de Curitiba

    Curitiba, Brazil

  • Centro Integrado de Pesquisa em Oncologia - Hospital Nossa Senhora da Conceio

    Porto Alegre, Brazil

  • Instituto Nacional de Cancer (INCA)

    Rio de Janeiro, Brazil

  • Instituto Americas - Ensino, Pesquisa e Inovacao

    Rio de Janeiro, Brazil

  • Oncoclinicas Rio de Janeiro S.A (Centro de Tratamento de Tumores Botafogo)

    Rio de Janeiro - RJ, Brazil

  • Instituto D'Or de Pesquisa e Ensino - Hospital Sao Rafael

    Salvador, Brazil

  • Hospital Alemao Oswaldo Cruz (HAOC)

    São Paulo, Brazil

  • Instituto Brasileiro de Controle do Cancer - IBCC Oncologia

    São Paulo, Brazil

  • CRIO - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • OC Oncoclinicas Oncovida

    Brasília, Destrito Federal, Brazil

  • Centro de Pesquisas Clinicas em Oncologia (CPCO)/HECI

    Cachoeiro de Itapemirim, Espírito Santo, Brazil

  • Associacao Feminina de Educacao e Combate ao Cancer(AFECC) - Hospital Santa Rita

    Vitória, Espírito Santo, Brazil

  • Hospital Santa Izabel, Santa Casa de Misericordia da Bahia

    Salvador, Estado de Bahia, Brazil

  • Cetus Oncologia S.A. Unidade Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Nucleo de Ensino Pesquisa e Inovacao Mario Penna

    Belo Horizonte, Minas Gerais, Brazil

  • Fundacao Sao Francisco Xavier - Hospital Marcio Cunha (HMC) - Unidade I

    Ipatinga, Minas Gerais, Brazil

Showing 40 of 218 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.